Table 2.
Summary results of pooled PFS, OS, and ORR by subgroup analysis
| Studies | Pooled PFS
|
Studies | Pooled OS
|
Studies | Pooled ORR
|
||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| BRCA mutation | 5 | 0.37 (0.22–0.63) | <0.001 | 5 | 0.78 (0.62–0.98) | 0.030 | 3 | 2.01 (1.42–2.85) | <0.001 |
| ATM deficiency | 2 | 0.74 (0.51–1.07) | 0.113 | 2 | 0.53 (0.26–1.08) | 0.080 | 2 | 1.70 (0.89–3.23) | 0.107 |
| Cancer type | |||||||||
| Ovarian cancer | 4 | 0.44 (0.30–0.67) | <0.001 | 4 | 0.83 (0.68–1.02) | 0.075 | 3 | 1.16 (0.92–1.47) | 0.205 |
| Breast cancer | 1 | 0.58 (0.43–0.79) | 0.001 | 1 | 0.90 (0.63–1.29) | 0.564 | 1 | 2.08 (1.40–3.10) | <0.001 |
| Lung cancer | 1 | 0.88 (0.69–1.13) | 0.321 | 1 | 0.99 (0.71–1.39) | 0.980 | NR | NR | NR |
| Gastric cancer | 2 | 0.83 (0.70–0.99) | 0.036 | 2 | 0.75 (0.62–0.90) | 0.002 | 2 | 1.51 (1.04–2.21) | 0.032 |
Abbreviations: ATM, ataxia telangiectasia, mutated; HR, hazard ratio; PFS, progression-free survival; OS, overall survival; ORR, overall response rate; NR, not reported; RR, risk ratio.